Abstract 1678P
Background
Chemotherapy alone has limited efficacy in treating advanced pancreatic cancer (APC). The addition of nimotuzumab (nimo) to gemcitabine had been shown to be more effective in our previous studies: the progression-free survival (PFS) was up to 5.1 months, 1.5 months longer than gemcitabine alone for 1st line treatment of APC, but its efficacy and safety in combination with other chemotherapy regimens are unknown.
Methods
In this study, patients with APC were treated with standard of care (routine chemotherapy) combined with or without nimo in a real-world data setting. Demographic and clinical data were collected from electronic medical records of First Affiliated Hospital of Xi’an Jiaotong University from April 2018 to May 2023. The primary efficacy endpoint was progression-free survival (PFS).
Results
We identified 282 APC patients, of which 36.8% received nimo combined with routine chemotherapy. After 1:1 propensity score matching (PSM), we created 65 pairs patients (median age was 62 years, range, 55-69) who received routine chemotherapy with or without nimo as first-line treatment. Among them, 55 pairs were treated with albumin paclitaxel-gemcitabine (AG), 3 pairs with gemcitabine-tegafur (GS) and 7 pairs with others. The median dosage of nimo was 400mg weekly. Up to May 2023, the median follow-up time was beyond 24 months. Survival analysis showed that nimo was associated with longer PFS (10.9 months vs 9.1 months; p<0.05, HR=0.5(95%CI, 0.29-0.88) after matching), but the OS was not evaluated due to the missing date of death. No grade 3 or above toxicities were observed.
Conclusions
Gemcitabine-based combination chemotherapy (eg, AG regimen, GS regimen) were commonly used as first-line treatment for APC in China. The addition of nimotuzumab to combination chemotherapy was a strong regimen and found to prolong the survival time for APC, with a manageable safety profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22